Takeda's Entyvio Beats Humira In Head-To-Head Ulcerative Colitis Trial

 
• By John Davis

Takeda’s gut-selective biologic vedolizumab pushes ahead of other biologics in the race to make its mark in ulcerative colitis, a therapeutic sector targeted by numerous new investigational therapies.  

Heads
Blinded double-dummy head-to-head studies may be key to driving change in the IBD marketplace • Source: Shutterstock

More from Alimentary/Metabolic

More from Therapy Areas